Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | S1PR3 | Q99500 | 10/20 | 0.38 |
| ▸ | S1PR4 | O95977 | 7/20 | 0.38 |
| ▸ | S1PR2 | O95136 | 3/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | S1PR1 | P21453 | 6/20 | 0.36 |
| ▸ | B3GNT2 | Q9NY97 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 4/20 | 0.35 |
| ▸ | NPC1 | O15118 | 2/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | GRN | P28799 | 1/20 | 0.33 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2512755 | 0.83 | NR1I2 (0.39) | KDM4EMAPK1GRNSORT1 | |
| SCHEMBL588485 | 0.83 | NR1I2 (0.39) | KDM4EMAPK1GRNSORT1 | |
| SCHEMBL589587 | 0.79 | CACNA1G (0.41) | KDM4ES1PR3S1PR1 | |
| SCHEMBL2099345 | 0.78 | KDM4E (0.41) | KDM4EALDH1A1S1PR3S1PR4S1PR2 | |
| SCHEMBL18921065 | 0.78 | S1PR4 (0.43) | KDM4EALDH1A1S1PR3S1PR4S1PR2 | |
| SCHEMBL15240217 | 0.76 | B3GNT2 (0.45) | KDM4EALDH1A1S1PR3S1PR4S1PR2 | |
| SCHEMBL18425730 | 0.72 | ALDH1A1 (0.41) | KDM4EALDH1A1S1PR3S1PR4S1PR2 | |
| SCHEMBL15240620 | 0.72 | AAK1 (0.42) | ALDH1A1S1PR3RAB9ANPC1MAPK1 | |
| SCHEMBL15240623 | 0.72 | AAK1 (0.42) | ALDH1A1S1PR3RAB9ANPC1MAPK1 | |
| SCHEMBL4983684 | 0.71 | FPR2 (0.39) | KDM4EALDH1A1RAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8114989-B2 | Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors | ASTRAZENECA AB (SE) | 2012-02-14 | — | — | US | disclosed |
| US-20100210648-A1 | PYRAZOLYLAMINOPYRIMIDINE DERIVATIVES USEFUL AS TYROSINE KINASE INHIBITORS | ASTRAZENECA R&D (SE) | 2010-08-19 | — | — | US | disclosed |
| US-20080287437-A1 | Pyrazolylaminopyrimidine Derivatives Useful as Tyrosine Kinase Inhibitors | ASTRAZENECA AB (SE) | 2008-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287437-A1 | Pyrazolylaminopyrimidine Derivatives Useful as Tyrosine Kinase Inhibitors | ABL1, FLT3, ERBB2 | KDM4E 1663/4885ALDH1A1 1326/4885S1PR3 1906/4885 |
| US-20100210648-A1 | PYRAZOLYLAMINOPYRIMIDINE DERIVATIVES USEFUL AS TYROSINE KINASE INHIBITORS | ABL1, FLT3, ERBB2 | KDM4E 1663/4885ALDH1A1 1326/4885S1PR3 1906/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.